The Prostate Cancer Registry: First results from an international, prospective, observational study of men with metastatic castration-resistant prostate cancer (mCRPC)

被引：1
|
作者：
Chowdhury, S. [1 ]
Birtle, A. J. [2 ]
Bjartell, A. [3 ]
Costa, L. [4 ,5 ]
Feyerabend, S. [6 ]
Galli, L. [7 ]
Lumen, N. [8 ]
Kalinka-Warzocha, E. [9 ]
Maroto, P. [10 ]
Matveev, V. B. [11 ]
Paiss, T. [12 ]
Spaeth, D. [13 ]
Klumper, E. [14 ]
Thingstad, T. [15 ]
Wapenaar, R. [16 ]
Lee, E. [17 ]
机构：
[1] Guys Hosp, Dept Urol, London SE1 9RT, England
[2] Royal Preston Hosp, Rosemere Canc Ctr, Preston, Lancs, England
[3] Skane Univ Hosp, Dept Urol, Malmo, Sweden
[4] Hosp Santa Maria, Lisbon, Portugal
[5] Univ Lisbon, Inst Med Mol, P-1699 Lisbon, Portugal
[6] Studienpraxis Urol, Nurtingen, Germany
[7] Azienda Osped Univ Pisana, Med Oncol, Pisa, Italy
[8] Ghent Univ Hosp, Dept Urol, Ghent, Belgium
[9] Wojewodzki Szpital Specjalistyczny Im M Kopernika, Lodz, Poland
[10] St Pau Hosp, Barcelona, Spain
[11] NN Blokhin Canc Res Ctr, Dept Oncourol, Moscow, Russia
[12] Urol Team Ulm, Ulm, Germany
[13] Ctr Oncol Gentilly, Nancy, France
[14] SMS Oncol BV, Amsterdam, Netherlands
[15] Janssen Cilag AS, Oslo, Norway
[16] Janssen Cilag BV, Tilburg, Netherlands
[17] Janssen Pharmaceut, EMEA Med Affairs, B-2340 Beerse, Belgium
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)31367-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2548
引用
收藏
页码：S492 / S492
页数：1
相关论文
共 50 条
  • [1] THE PROSTATE CANCER REGISTRY: ANALYSIS OF MEDICAL RESOURCE UTILISATION (MRU) IN AN INTERNATIONAL, PROSPECTIVE, OBSERVATIONAL STUDY OF MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
    Chowdhury, S.
    Birtle, A.
    Bjartell, A.
    Costa, L.
    Feyerabend, S.
    Galli, L.
    Lumen, N.
    Kalinka-Warzocha, E.
    Maroto, P.
    Matveev, V
    Paiss, T.
    Spaeth, D.
    Dearden, L.
    Klumper, E.
    Thingstad, T.
    Wapenaar, R.
    Lee, E.
    VALUE IN HEALTH, 2015, 18 (07) : A482 - A482
  • [2] Dexamethasone in pretreated men with metastatic castration-resistant prostate cancer (mCRPC): A prospective study.
    Baciarello, Giulia
    Hamilou, Zineb
    Chebib, Ralph
    Albiges, Laurence
    Fuerea, Alina
    Loriot, Yohann
    Massard, Christophe
    Colomba, Emeline
    Di Palma, Mario
    Escudier, Bernard
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [3] Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry
    Bjartell, Anders
    Costa, Luis
    Kramer, Gero
    Zurawski, Bogdan
    Galli, Luca
    Werbrouck, Patrick
    Ecke, Thorsten
    Parikh, Omi
    Bennamoun, Mostefa
    Freire, Camilo Garcia
    Peer, Avivit
    Ljungberg, Borje
    Cicin, Irfan
    Smith, Emma
    Lukac, Martin
    Wapenaar, Robert
    Chowdhury, Simon
    EUROPEAN UROLOGY OPEN SCIENCE, 2022, 45 : 12 - 22
  • [4] The prostate cancer registry: Patient characteristics, treatments and preliminary outcomes from a large observational study of metastatic castration-resistant prostate cancer (mCRPC)
    Chowdhury, S.
    Birtle, A. J.
    Bjartell, A.
    Costa, L. A. M.
    Feyerabend, S.
    Galli, L.
    Kalinka-Warzocha, E.
    Kramer, G.
    Maroto Rey, J. P.
    Lumen, N.
    Matveev, V. B.
    Paiss, T.
    Spaeth, D.
    Antoni, L.
    Klumper, E.
    Wapenaar, R.
    Lee, E.
    ANNALS OF ONCOLOGY, 2016, 27
  • [5] Avelumab in metastatic castration-resistant prostate cancer (mCRPC).
    Fakhrejahani, Farhad
    Madan, Ravi Amrit
    Dahut, William L.
    Bilusic, Marijo
    Karzai, Fatima
    Cordes, Lisa M.
    Strauss, Julius
    Schlom, Jeffrey
    Gulley, James L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Avelumab in metastatic castration-resistant prostate cancer (mCRPC).
    Fakhrejahani, Farhad
    Madan, Ravi Amrit
    Dahut, William L.
    Karzai, Fatima
    Cordes, Lisa M.
    Schlom, Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [7] Treatment outcomes in men with metastatic castration-resistant prostate cancer (mCRPC) and cardiovascular disorders or diabetes: The Prostate Cancer Registry.
    Lumen, Nicolaas
    Chowdhury, Simon
    Birtle, Alison J.
    Bjartell, Anders
    Costa, Luis
    Feyerabend, Susan
    Galli, Luca
    Kalinka-Warzocha, Ewa
    Kramer, Gero
    Maroto, Pablo
    Matveev, Vsevolod B.
    Paiss, Thomas
    Pisconti, Salvatore
    Spaeth, Dominique
    Veiga, Francisco Gomez
    Antoni, Laurent
    Klumper, Edwin
    Wapenaar, Robert
    Thoret-Bauchet, Florence
    Lee, Emma
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] ARN-509 in men with metastatic castration-resistant prostate cancer (mCRPC)
    Rathkopf, Dana E.
    Antonarakis, Emmanuel S.
    Shore, Neal D.
    Tutrone, Ronald
    Alumkal, Joshi J.
    Ryan, Charles J.
    Saleh, Mansoor N.
    Hauke, Ralph J.
    Maneval, Edna Chow
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [9] Pembrolizumab in men with heavily treated metastatic castration-resistant prostate cancer (mCRPC).
    Tucker, Matthew D.
    Zhu, Jason
    Berry, William R.
    Ramalingam, Sundhar
    Zhang, Tian
    Harrison, Michael Roger
    Wu, Yuan
    Healy, Patrick
    George, Daniel J.
    Armstrong, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [10] Docetaxel in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC): an Observational Study in a Single Institution
    Schallier, D.
    Decoster, L.
    Braeckman, J.
    Fontaine, C.
    Degreve, J.
    ANTICANCER RESEARCH, 2012, 32 (02) : 633 - 641
12345